| Literature DB >> 24245826 |
Patrick Duckney1, Heng Kuan Wong, José Serrano, Diaraf Yaradou, Thierry Oddos, Georgios N Stamatas.
Abstract
BACKGROUND: Skin resident microbial species are often thought of either as pathogenic or commensal. However, little is known about the role of the skin barrier in modulating their potential for causing disease. To investigate this question we measured the effects of three microbial species commonly found on the skin (Staphylococcus epidermidis, Staphylococcus aureus, and Propionibacterium acnes) on a reconstructed human epidermal model by either applying the bacteria on the model surface (intact barrier) or adding them to the culture medium (simulating barrier breach).Entities:
Mesh:
Substances:
Year: 2013 PMID: 24245826 PMCID: PMC4225502 DOI: 10.1186/1756-0500-6-474
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Figure 1and added to the medium of reconstructed human epidermal equivalents induce dose-dependent proinflammatory and cytotoxic reactions. After 24 hrs incubation with bacteria at 1 × 107, 1 × 108 and 1 × 109 CFU, the interleukin (IL)-1α (A), IL-8 (B) and TNFα (C) levels in the RHE growth medium were measured. The cell viability (D) was assessed by measuring leakage of cytoplasmic Lactate Dehydrogenase (LDH) into the RHE growth medium. Data are expressed as percentage of untreated control (UnC = 100%) and are presented as mean ± one standard deviation. Single and double asterisks indicate statistically significant differences (P < 0.05 and P < 0.01) versus the untreated control.
Figure 2added to the medium of reconstructed human epidermal equivalents induces strong proinflammatory and cytotoxic reactions. After 24 hrs incubation with bacteria at 1 × 107, 1 × 108 and 1 × 109 CFU, the interleukin (IL)-1α (A), IL-8 (B) and TNFα (C) levels in the RHE growth medium were measured. The cell viability (D) was assessed by measuring leakage of cytoplasmic Lactate Dehydrogenase (LDH) into the RHE growth medium. Data are expressed as percentage of untreated control (UnC = 100%) and are presented as mean ± one standard deviation. Single and double asterisks indicate statistically significant differences (P < 0.05 and P < 0.01) versus the untreated control.
Figure 3(A) and (B) added to the medium of reconstructed human epidermal equivalents induce dose-dependent changes in the expression of genes involved in differentiation (FLG, TG1, CLD, OCCL) and proliferation (PCNA). After 24 hrs incubation with bacteria at 1 × 107, 1 × 108 and 1 × 109 CFU, RNA from the RHEs was extracted and reverse transcribed. The mRNA expression levels of a range of genes were determined by quantitative reverse transcription polymerase chain reaction. The amount of target transcripts was normalized using an 18S RNA normalization gene. Data are expressed as percentage of untreated control (UnC = 100%) and are presented as mean ± one standard deviation. Asterisks indicate statistically significant differences (P < 0.05) vs the untreated control.
Average release of the proinflammatory cytokines IL-1α, IL-8, TNFα (pg/ml) and LDH (measured by optical absorbance at 490 nm) from RHE 24 hours after topical treatment with , and at different concentrations
| | ||||
| [IL-1α] released | 100 ± 3.5 | 116 ± 111.2 | 143.6 ± 156.8 | 186.8 ± 215.8 |
| [IL-8] released | 100 ± 18.4 | 151.7 ± 248.8 | 118.9 ± 156 | 193.4 ± 239.5* |
| [TNFα] released | 100 ± 0.6 | 124.4 ± 35.6 | 138 ± 77.1 | 151.8 ± 80.7 |
| LDH absorbance | 100 ± 0.03 | 83.6 ± 63.2 | 82.6 ± 62.9 | 88.6 ± 58.2 |
| | ||||
| [IL-1α] released | 100 ± 8.28 | 123.1 ± 100.3 | 122 ± 91 | 133.4 ± 112.1 |
| [IL-8] released | 100 ± 42.08 | 120.7 ± 129.6 | 109.5 ± 97.3 | 107.1 ± 84.9 |
| [TNFα] released | 100 ± 1.6 | 162.6 ± 158.1 | 115.7 ± 126.1 | 88.6 ± 113.6 |
| LDH absorbance | 100 ± 0.04 | 100.2 ± 148.4 | 108.8 ± 161.6 | 102.1 ± 142.8 |
| | ||||
| [IL-1α] released | 100 ± 2.3 | 157.6 ± 303.8 | 1062.1 ± 3556.2 | 1251.7 ± 3735.6 |
| [IL-8] released | 100 ± 12.1 | 60.4 ± 27.7 | 93.1 ± 95.1 | 73 ± 2.6 |
| LDH absorbance | 100 ± 0.1 | 273.3 ± 357.5 | 505.2 ± 1002 | 666.4 ± 1321 |
Results are expressed as percentage of the untreated control.
*Single asterisk indicate statistically significant differences (P < 0.05) versus the untreated control.
Average expression of the RHE differentiation markers FLG, TG1, CLD, OCCL and the proliferation marker PCNA (measured as % expression of untreated control) 24 hours after topical treatment with and at different concentrations
| | | | | |
| FLG | 100 ± 21.1 | 105 ± 50.5 | 113 ± 60 | 99 ± 37.4 |
| TG1 | 100 ± 11 | 95 ± 30.7 | 95 ± 33.5 | 92 ± 25.8 |
| CLD | 100 ± 29.2 | 142 ± 68.3 | 161 ± 105.2 | 123 ± 53.5 |
| OCCL | 100 ± 17.2 | 84 ± 30.9 | 95 ± 35.4 | 113 ± 63.8 |
| PCNA | 100 ± 25.3 | 129 ± 36.2 | 120 ± 39.2 | 135 ± 34 |
| | | | | |
| FLG | 100 ± 28 | 110 ± 26.5 | 101 ± 42 | 99 ± 31.4 |
| TG1 | 100 ± 26.9 | 125 ± 74.7 | 84 ± 29.9 | 77 ± 34.6 |
| CLD | 100 ± 36.5 | 90 ± 35.7 | 71 ± 32.1 | 84 ± 31.6 |
| OCCL | 100 ± 33.4 | 112 ± 72.9 | 81 ± 40.5 | 97 ± 42.6 |
| PCNA | 100 ± 18.6 | 102 ± 49.4 | 132 ± 108.2 | 140 ± 93.9 |
| | ||||
| FLG | 100 ± 19.3 | 121 ± 32.6 | 107 ± 20.5 | 141 ± 45.9 |
| TG1 | 100 ± 12 | 179 ± 65.8 | 112 ± 31.7 | 114 ± 34.3 |
| CLD | 100 ± 22.4 | 107 ± 25.3 | 126 ± 30.2 | 141 ± 43.8 |
| OCCL | 100 ± 31.9 | 139 ± 67.7 | 141 ± 43.9 | 143 ± 45.7 |
| PCNA | 100 ± 18 | 104 ± 22.6 | 98 ± 14.3 | 97 ± 48 |
*Single asterisk indicate statistically significant differences (P < 0.05) versus the untreated control.
Sense and antisense primer sequences used in qPCR
| 18S Ribosomal RNA gene | | Forward | 5'-TAAGTCCCTGCCCTTTGTACACA-3' |
| Reverse | 5'-GATCCGAGGGCCTCACTAAAC-3' | ||
| Profilaggrin | FLG | Forward | 5'-TGGCAAATCATCATCTCAAGTG-3' |
| Reverse | 5'-CTGTCCTGGCTAACTCTGG-3' | ||
| Occludin | OCCL | Forward | 5'-CAAGCGGTTTTATCCAGAGTC-3' |
| Reverse | 5'-AAGTCATCCACAGGCGAAG-3' | ||
| Claudin1 | CLD1 | Forward | 5'-AGTGCTTGGAAGACGATGAG-3' |
| Reverse | 5'-TTGAACGATTCTATTGCCATACC-3' | ||
| Transglutaminase 1 | TG1 | Forward | 5'-TGCTGGATGCCTGCTTATAC-3' |
| Reverse | 5'-TGCCTCGGGAGTAATCACC-3' | ||
| Proliferating cell nuclear antigen | PCNA | Forward | 5'-AACCTCACCAGTATGTCC-3' |
| Reverse | 5'-ATCCATCAACTTCATTTCATAG-3’ |